Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991522 | 0.83 | PI4KB (0.57) | MAPK14PI4KBCYP3A4 | |
| SCHEMBL4539855 | 0.72 | SMN1; SMN2 (0.58) | — | |
| SCHEMBL18057142 | 0.68 | FABP4 (0.42) | MAPK14PI4KBCYP3A4 | |
| SCHEMBL6737392 | 0.67 | CDK9 (0.35) | — | |
| SCHEMBL18058952 | 0.67 | PI4KB (0.58) | MAPK14PI4KBCYP3A4 | |
| SCHEMBL989419 | 0.66 | MAPK14 (0.49) | MAPK14PI4KBCYP3A4 | |
| SCHEMBL3491096 | 0.65 | SMN1; SMN2 (0.50) | — | |
| SCHEMBL19840303 | 0.64 | MAPK14 (0.55) | MAPK14PI4KBCYP3A4 | |
| SCHEMBL4830269 | 0.64 | PI4KB (0.55) | MAPK14PI4KBCYP3A4 | |
| SCHEMBL4830340 | 0.64 | MAPK14 (0.39) | MAPK14PI4KBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1554272-B1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | MAPK14 10/4885PI4KB 282/4885CYP3A4 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.